CA2360549C - Double nuclear transfer method and results thereof - Google Patents
Double nuclear transfer method and results thereof Download PDFInfo
- Publication number
- CA2360549C CA2360549C CA2360549A CA2360549A CA2360549C CA 2360549 C CA2360549 C CA 2360549C CA 2360549 A CA2360549 A CA 2360549A CA 2360549 A CA2360549 A CA 2360549A CA 2360549 C CA2360549 C CA 2360549C
- Authority
- CA
- Canada
- Prior art keywords
- cell
- oocyte
- embryo
- nucleus
- recipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000012546 transfer Methods 0.000 title claims abstract description 164
- 238000000034 method Methods 0.000 title claims abstract description 132
- 210000000287 oocyte Anatomy 0.000 claims abstract description 171
- 210000004027 cell Anatomy 0.000 claims abstract description 166
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 106
- 241001465754 Metazoa Species 0.000 claims abstract description 50
- 230000008569 process Effects 0.000 claims abstract description 20
- 239000007924 injection Substances 0.000 claims description 45
- 238000002347 injection Methods 0.000 claims description 45
- 238000011161 development Methods 0.000 claims description 41
- 230000018109 developmental process Effects 0.000 claims description 41
- 230000022131 cell cycle Effects 0.000 claims description 38
- 238000001727 in vivo Methods 0.000 claims description 30
- 238000000338 in vitro Methods 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 27
- 241000894007 species Species 0.000 claims description 21
- 230000007910 cell fusion Effects 0.000 claims description 18
- 241000283690 Bos taurus Species 0.000 claims description 16
- 230000031864 metaphase Effects 0.000 claims description 16
- 230000000394 mitotic effect Effects 0.000 claims description 10
- 208000035199 Tetraploidy Diseases 0.000 claims description 8
- 241001494479 Pecora Species 0.000 claims description 7
- 230000018199 S phase Effects 0.000 claims description 7
- 241000283707 Capra Species 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000010190 G1 phase Effects 0.000 claims description 3
- 241000283953 Lagomorpha Species 0.000 claims description 3
- 241000282898 Sus scrofa Species 0.000 claims description 3
- 241000030939 Bubalus bubalis Species 0.000 claims description 2
- 241000282836 Camelus dromedarius Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims description 2
- 230000001488 breeding effect Effects 0.000 claims description 2
- 244000309464 bull Species 0.000 claims description 2
- 210000001840 diploid cell Anatomy 0.000 claims description 2
- 230000013020 embryo development Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 49
- 102000004169 proteins and genes Human genes 0.000 abstract description 41
- 238000004519 manufacturing process Methods 0.000 abstract description 29
- 239000000463 material Substances 0.000 abstract description 16
- 238000012239 gene modification Methods 0.000 abstract description 15
- 230000005017 genetic modification Effects 0.000 abstract description 15
- 235000013617 genetically modified food Nutrition 0.000 abstract description 15
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 238000004113 cell culture Methods 0.000 abstract description 2
- 238000012248 genetic selection Methods 0.000 abstract description 2
- 210000002257 embryonic structure Anatomy 0.000 description 84
- 239000002609 medium Substances 0.000 description 73
- 230000004913 activation Effects 0.000 description 63
- 230000004927 fusion Effects 0.000 description 50
- 210000004940 nucleus Anatomy 0.000 description 50
- 230000007159 enucleation Effects 0.000 description 33
- 210000000805 cytoplasm Anatomy 0.000 description 28
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 27
- 239000011575 calcium Substances 0.000 description 27
- 239000000126 substance Substances 0.000 description 27
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 25
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 25
- 230000035800 maturation Effects 0.000 description 25
- 230000001360 synchronised effect Effects 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 24
- 229910052791 calcium Inorganic materials 0.000 description 24
- 108010077544 Chromatin Proteins 0.000 description 23
- 210000003483 chromatin Anatomy 0.000 description 23
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 23
- 210000003101 oviduct Anatomy 0.000 description 20
- 210000004508 polar body Anatomy 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 230000035935 pregnancy Effects 0.000 description 16
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 15
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 15
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 14
- 229950006344 nocodazole Drugs 0.000 description 14
- 230000001419 dependent effect Effects 0.000 description 13
- 210000002503 granulosa cell Anatomy 0.000 description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 11
- 229930195725 Mannitol Natural products 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000000594 mannitol Substances 0.000 description 11
- 235000010355 mannitol Nutrition 0.000 description 11
- 230000008774 maternal effect Effects 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 210000004340 zona pellucida Anatomy 0.000 description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 229940050570 regu-mate Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- VWAUPFMBXBWEQY-ANULTFPQSA-N Altrenogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC=C)C=C3)C3=C21 VWAUPFMBXBWEQY-ANULTFPQSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229960000971 altrenogest Drugs 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 210000004748 cultured cell Anatomy 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 241000282887 Suidae Species 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 210000002459 blastocyst Anatomy 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000011010 flushing procedure Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000011278 mitosis Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 229910001868 water Inorganic materials 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 210000001109 blastomere Anatomy 0.000 description 6
- 244000309466 calf Species 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 229940028334 follicle stimulating hormone Drugs 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 230000000366 juvenile effect Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000012800 visualization Methods 0.000 description 6
- 230000010337 G2 phase Effects 0.000 description 5
- 230000027311 M phase Effects 0.000 description 5
- 206010042573 Superovulation Diseases 0.000 description 5
- 210000001771 cumulus cell Anatomy 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 4
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 4
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 4
- 239000012888 bovine serum Substances 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002224 dissection Methods 0.000 description 4
- 229940032383 estrumate Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- IFEJLMHZNQJGQU-KXXGZHCCSA-M sodium;(z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound [Na+].C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC([O-])=O)OC1=CC=CC(Cl)=C1 IFEJLMHZNQJGQU-KXXGZHCCSA-M 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000003307 slaughter Methods 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000016853 telophase Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 108010037003 Buserelin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 238000003744 In vitro fertilisation Methods 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 2
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 2
- 229960002719 buserelin Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000001733 follicular fluid Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 1
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 238000010449 nuclear transplantation Methods 0.000 description 1
- 230000008182 oocyte development Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 230000001776 parthenogenetic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 101150003374 sor2 gene Proteins 0.000 description 1
- 230000015887 sperm entry Effects 0.000 description 1
- 230000024477 spindle organization Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000027223 tetraploidy syndrome Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/04—Cells produced using nuclear transfer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9900734 | 1999-01-13 | ||
| GB9900734.6 | 1999-01-13 | ||
| US13054699P | 1999-04-22 | 1999-04-22 | |
| US60/130,546 | 1999-04-22 | ||
| PCT/GB2000/000086 WO2000042174A1 (en) | 1999-01-13 | 2000-01-13 | Double nuclear transfer method and results thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2360549A1 CA2360549A1 (en) | 2000-07-20 |
| CA2360549C true CA2360549C (en) | 2013-04-09 |
Family
ID=26314982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2360549A Expired - Lifetime CA2360549C (en) | 1999-01-13 | 2000-01-13 | Double nuclear transfer method and results thereof |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1141265B1 (enExample) |
| JP (1) | JP2002534118A (enExample) |
| AT (1) | ATE407203T1 (enExample) |
| AU (2) | AU780809B2 (enExample) |
| CA (1) | CA2360549C (enExample) |
| DE (1) | DE60040134D1 (enExample) |
| NZ (1) | NZ550899A (enExample) |
| WO (1) | WO2000042174A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6218899A (en) | 1998-10-12 | 2000-05-01 | Geron Bio-Med Limited | Porcine oocytes with improved developmental competence |
| US7414170B2 (en) | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
| US7074983B2 (en) | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
| AU2001278204A1 (en) * | 2000-08-01 | 2002-02-13 | Xy Genetics, Llc | Methods of selecting and cloning animals |
| WO2002019811A2 (en) * | 2000-09-06 | 2002-03-14 | Nexia Biotechnologies, Inc. | Generation of transgenic animals using nuclear transfer and oocytes at the germinal vesicle stage |
| CA2425100A1 (en) * | 2000-10-06 | 2002-04-11 | Advanced Cell Technology, Inc. | Method for generating cloned animals using chromosome shuffling |
| US7491534B2 (en) | 2000-12-22 | 2009-02-17 | Kirin Holdings Kabushiki Kaisha | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
| ATE502106T1 (de) | 2000-12-22 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Verfahren zur klonierung von nichtmenschliche säugern unter verwendung von reprogrammiertem donorchromatin oder donorzellen |
| JP3842597B2 (ja) | 2001-08-14 | 2006-11-08 | 家畜受精卵移植技術研究組合 | Ｇ１期細胞の収集方法及び該細胞を用いた核移植方法 |
| US20040025193A1 (en) * | 2002-08-01 | 2004-02-05 | Yann Echelard | Method for the rapid selection of homozygous primary cell lines for the production of transgenic animals by somatic cell nuclear transfer |
| EP1563084A4 (en) | 2002-11-08 | 2006-03-01 | Hematech Llc | TRANSGENE UNGULATES WITH REDUCED PRION PROTEIN ACTIVITY AND USES THEREOF |
| JP2006522609A (ja) * | 2003-04-09 | 2006-10-05 | マギー−ウイメンズ・ヘルス・コーポレイション | 動物の体細胞核移植と関係する紡錘体欠損を修正するための方法 |
| AU2004259019B2 (en) | 2003-07-21 | 2010-09-23 | Lifecell Corporation | Acellular tissue matrices made from galactose alpha-1,3-galactose-deficient tissue |
| US7420099B2 (en) | 2004-04-22 | 2008-09-02 | Kirin Holdings Kabushiki Kaisha | Transgenic animals and uses thereof |
| US8524454B2 (en) | 2006-04-07 | 2013-09-03 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
| CN102763625A (zh) * | 2012-07-28 | 2012-11-07 | 湖南农业大学 | 中华鳖伪雌鳖及全雄中华鳖的培育方法 |
| ES2846758T3 (es) | 2013-11-04 | 2021-07-29 | Lifecell Corp | Métodos para eliminar la alfa-galactosa |
| US20220267804A1 (en) * | 2017-11-20 | 2022-08-25 | Inguran, Llc | Methods for increasing the rate of genetic progress and generating inbred lines in non-human mammals |
| CN108244037A (zh) * | 2018-01-22 | 2018-07-06 | 孝感市鲁建农业开发有限公司 | 一种竹鼠养殖方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9517779D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517780D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| NZ337495A (en) * | 1997-03-06 | 2001-06-29 | Infigen Inc | Bovine primordial germ cells and their use in cloning |
| WO1998057538A1 (en) * | 1997-06-18 | 1998-12-23 | The Curators Of The University Of Missouri | Complete activation of mammalian oocytes |
-
2000
- 2000-01-13 WO PCT/GB2000/000086 patent/WO2000042174A1/en not_active Ceased
- 2000-01-13 AU AU19946/00A patent/AU780809B2/en not_active Ceased
- 2000-01-13 DE DE60040134T patent/DE60040134D1/de not_active Expired - Lifetime
- 2000-01-13 JP JP2000593731A patent/JP2002534118A/ja active Pending
- 2000-01-13 AT AT00900283T patent/ATE407203T1/de not_active IP Right Cessation
- 2000-01-13 EP EP00900283A patent/EP1141265B1/en not_active Expired - Lifetime
- 2000-01-13 NZ NZ550899A patent/NZ550899A/en not_active IP Right Cessation
- 2000-01-13 CA CA2360549A patent/CA2360549C/en not_active Expired - Lifetime
-
2005
- 2005-07-18 AU AU2005203115A patent/AU2005203115A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60040134D1 (enExample) | 2008-10-16 |
| JP2002534118A (ja) | 2002-10-15 |
| AU2005203115A1 (en) | 2005-08-11 |
| AU1994600A (en) | 2000-08-01 |
| CA2360549A1 (en) | 2000-07-20 |
| NZ550899A (en) | 2008-07-31 |
| ATE407203T1 (de) | 2008-09-15 |
| AU780809B2 (en) | 2005-04-21 |
| EP1141265A1 (en) | 2001-10-10 |
| EP1141265B1 (en) | 2008-09-03 |
| WO2000042174A1 (en) | 2000-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | Influence of nuclear and cytoplasmic activity on the development in vivo of sheep embryos after nuclear transplantation | |
| EP1141265B1 (en) | Double nuclear transfer method and results thereof | |
| CA2229568C (en) | Quiescent cell populations for nuclear transfer | |
| WO1999034669A1 (en) | Cloning using donor nuclei from differentiated fetal and adult cells | |
| JP2002500864A (ja) | 成体の体細胞核を再構成した被核除去卵母細胞からの動物の満期の成長 | |
| EP1017422A1 (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
| US7531715B1 (en) | Double nuclear transfer method and results thereof | |
| NZ337792A (en) | Nuclear transfer and use in cloning | |
| Eyestone et al. | Nuclear transfer from somatic cells: applications in farm animal species | |
| US7547549B2 (en) | Method to produce a hybrid cell having a single mitochondrial genotype | |
| AU2008203109A1 (en) | Double nuclear transfer method and results thereof | |
| AU2003271356B2 (en) | Quiescent cell population for nuclear transfer | |
| Landry | Reconstruction of nuclear transfer embryos in goats and cattle [electronic resource] | |
| Chen | Manipulation of oocyte maturation to improve porcine somatic cell nuclear transfer | |
| MXPA98001646A (en) | Cellular populations inactive for transfer celu | |
| AU2005246962A1 (en) | Quiescent cell population for nuclear transfer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20200113 |